News Related to Unresectable or Metastatic HER2-Positive Breast Cancer

Related coverage linked through entity extraction aliases.

AstraZeneca's ENHERTU and CALQUENCE Reach Key Regulatory Milestones in Oncology

Feb 26, 2026

AstraZeneca's CALQUENCE received FDA approval as the first all-oral, fixed-duration regimen for chronic lymphocytic leukemia, while the EMA validated the marketing authorization application for ENHERTU in HER2-positive breast cancer treatment.

Enhertu Plus Pertuzumab Approved for First-Line HER2+ Metastatic Breast Cancer

Feb 24, 2026

Enhertu combined with pertuzumab received FDA approval for first-line treatment of HER2-positive metastatic breast cancer, marking the first new treatment in a decade. Real-world data show trastuzumab deruxtecan efficacy is consistent across patient subgroups.